S-18986

Last updated
S-18986
S-18986.svg
Legal status
Legal status
Identifiers
  • (S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C10H12N2O2S
Molar mass 224.28 g·mol−1
3D model (JSmol)
  • C1C[C@@H]2NS(=O)(=O)C3=CC=CC=C3N2C1
  • InChI=1S/C10H12N2O2S/c13-15(14)9-5-2-1-4-8(9)12-7-3-6-10(12)11-15/h1-2,4-5,10-11H,3,6-7H2/t10-/m1/s1 X mark.svgN
  • Key:MNTIJYGEITVWHU-SNVBAGLBSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

S-18986 is a positive allosteric modulator of the AMPA receptor related to cyclothiazide. It has nootropic and neuroprotective effects in animal studies, and induces both production of BDNF and AMPA-mediated release of noradrenaline and acetylcholine in the hippocampus and frontal cortex of the brain. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10]

See also

Related Research Articles

Racetams are a class of drugs that share a pyrrolidone nucleus. Some, such as piracetam, aniracetam, oxiracetam, pramiracetam and phenylpiracetam are considered nootropics. Others such as levetiracetam, brivaracetam, and seletracetam are anticonvulsants.

<span class="mw-page-title-main">Allopregnanolone</span> Endogenous inhibitory neurosteroid

Allopregnanolone is a naturally occurring neurosteroid which is made in the body from the hormone progesterone. As a medication, allopregnanolone is referred to as brexanolone, sold under the brand name Zulresso, and used to treat postpartum depression. It is used by injection into a vein over a 60-hour period under medical supervision.

<span class="mw-page-title-main">CX614</span> Chemical compound

CX-614 is an ampakine drug developed by Cortex Pharmaceuticals. It has been investigated for its effect on AMPA receptors.

<span class="mw-page-title-main">Metabotropic glutamate receptor 2</span> Mammalian protein found in Homo sapiens

Metabotropic glutamate receptor 2 (mGluR2) is a protein that, in humans, is encoded by the GRM2 gene. mGluR2 is a G protein-coupled receptor (GPCR) that couples with the Gi alpha subunit. The receptor functions as an autoreceptor for glutamate, that upon activation, inhibits the emptying of vesicular contents at the presynaptic terminal of glutamatergic neurons.

<span class="mw-page-title-main">Alpha-7 nicotinic receptor</span>

The alpha-7 nicotinic receptor, also known as the α7 receptor, is a type of nicotinic acetylcholine receptor implicated in long-term memory, consisting entirely of α7 subunits. As with other nicotinic acetylcholine receptors, functional α7 receptors are pentameric [i.e., (α7)5 stoichiometry].

<span class="mw-page-title-main">IDRA-21</span> Chemical compound

IDRA-21 is a positive allosteric modulator of the AMPA receptor and a benzothiadiazine derivative. It is a chiral molecule, with (+)-IDRA-21 being the active form.

<span class="mw-page-title-main">LY-503430</span> Chemical compound

LY-503430 is an AMPA receptor positive allosteric modulator developed by Eli Lilly.

<span class="mw-page-title-main">PEPA (drug)</span> Chemical compound

PEPA is a sulfonamide AMPA receptor positive allosteric modulator, which is up to 100 times more potent than aniracetam in vitro. It produces memory-enhancing effects in rats when administered intravenously.

<span class="mw-page-title-main">Cyclothiazide</span> Chemical compound

Cyclothiazide, sometimes abbreviated CTZ, is a benzothiadiazide (thiazide) diuretic and antihypertensive that was originally introduced in the United States in 1963 by Eli Lilly and was subsequently also marketed in Europe and Japan. Related drugs include diazoxide, hydrochlorothiazide, and chlorothiazide.

<span class="mw-page-title-main">LY-404187</span> Chemical compound

LY-404187 is an AMPA receptor positive allosteric modulator which was developed by Eli Lilly and Company. It is a member of the biarylpropylsulfonamide class of AMPA receptor potentiators.

<span class="mw-page-title-main">5-Fluorowillardiine</span> Chemical compound

5-Fluorowillardiine is a selective agonist for the AMPA receptor, with only limited effects at the kainate receptor. It is an excitotoxic neurotoxin when used in vivo and so is rarely used in intact animals, but it is widely used to selectively stimulate AMPA receptors in vitro. It is structurally similar to the compound willardiine, which is also an agonist for the AMPA and kainate receptors. Willardiine occurs naturally in Mariosousa willardiana and Acacia sensu lato.

<span class="mw-page-title-main">GYKI 52466</span> Chemical compound

GYKI 52466 is a 2,3-benzodiazepine that acts as an ionotropic glutamate receptor antagonist, which is a non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA-, kainate- and NMDA-induced responses respectively), orally-active anticonvulsant, and skeletal muscle relaxant. Unlike conventional 1,4-benzodiazepines, GYKI 52466 and related 2,3-benzodiazepines do not act on GABAA receptors. Like other AMPA receptor antagonists, GYKI 52466 has anticonvulsant and neuroprotective properties.

In pharmacology and biochemistry, allosteric modulators are a group of substances that bind to a receptor to change that receptor's response to stimulus. Some of them, like benzodiazepines, are drugs. The site that an allosteric modulator binds to is not the same one to which an endogenous agonist of the receptor would bind. Modulators and agonists can both be called receptor ligands.

<span class="mw-page-title-main">Unifiram</span> Chemical compound

Unifiram is an experimental drug. that has antiamnesic and other effects in animal studies with far greater potency than piracetam. A number of related compounds are known, such as sunifiram (DM-235) and sapunifiram (MN-19). Unifiram has two enantiomers, with the dextro form being the more active isomer. It has been shown to reduce the duration of hypnosis induced by pentobarbital, without impairing motor coordination. As of 2015, no formal human studies with unifiram have been conducted. Unifiram is not patented and, despite the lack of human and long-term toxicity studies, it is commonly sold online.

<span class="mw-page-title-main">LY-487,379</span>

LY-487,379 is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2. It is used to study the structure and function of this receptor subtype, and LY-487,379 along with various other mGluR2/3 agonists and positive modulators are being investigated as possible antipsychotic and anxiolytic drugs.

<span class="mw-page-title-main">ORG-26576</span> Ampakine

ORG-26576 is an ampakine originally developed by Cortex Pharmaceuticals and then licensed to Organon International for development. In animal studies it has been shown to effectively potentiate AMPA receptor function, leading to increased BDNF release and enhanced neuronal differentiation and survival, as well as producing nootropic effects in standardised assays. Development as an antidepressant has been halted due to a failed Phase II trial for major depressive disorder.

<span class="mw-page-title-main">Mibampator</span>

Mibampator is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which was under development by Eli Lilly for the treatment of agitation/aggression in Alzheimer's disease but was never marketed. It reached phase II clinical trials prior to the discontinuation of its development.

<span class="mw-page-title-main">Tulrampator</span> Chemical compound

Tulrampator is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which is under development by RespireRx Pharmaceuticals and Servier for the treatment of major depressive disorder, Alzheimer's disease, dementia, and mild cognitive impairment. Tulrampator was in phase II clinical trial for depression, but failed to show superiority over placebo. There are also phase II clinical trials for Alzheimer's disease and phase I trials for dementia and mild cognitive impairment.

<span class="mw-page-title-main">AMPA receptor positive allosteric modulator</span>

AMPA receptor positive allosteric modulators are positive allosteric modulators (PAMs) of the AMPA receptor (AMPR), a type of ionotropic glutamate receptor which mediates most fast synaptic neurotransmission in the central nervous system.

<span class="mw-page-title-main">AZ12216052</span>

AZ-12216052 is a drug which acts as a potent and selective positive allosteric modulator of the metabotropic glutamate receptor 8, and is used for research into the role of this receptor subtype in various processes including anxiety and neuropathic pain.

References

  1. Lockhart B, Iop F, Closier M, Lestage P (August 2000). "(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated [3H]noradrenaline release from rat hippocampal and frontal cortex slices". European Journal of Pharmacology. 401 (2): 145–53. doi:10.1016/S0014-2999(00)00433-7. PMID   10924919.
  2. Lebrun C, Pillière E, Lestage P (August 2000). "Effects of S 18986-1, a novel cognitive enhancer, on memory performances in an object recognition task in rats". European Journal of Pharmacology. 401 (2): 205–12. doi:10.1016/S0014-2999(00)00429-5. PMID   10924928.
  3. Dicou E, Rangon CM, Guimiot F, Spedding M, Gressens P (April 2003). "Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain". Brain Research. 970 (1–2): 221–5. doi:10.1016/S0006-8993(03)02357-6. PMID   12706264. S2CID   22186254.
  4. Rosi S, Giovannini MG, Lestage PJ, Muñoz C, Corte LD, Pepeu G (May 2004). "S 18986, a positive modulator of AMPA receptors with cognition-enhancing properties, increases ACh release in the hippocampus of young and aged rat". Neuroscience Letters. 361 (1–3): 120–3. doi:10.1016/j.neulet.2003.12.061. PMID   15135908. S2CID   12800129.
  5. Bourasset F, Bernard K, Muñoz C, Genissel P, Scherrmann JM (August 2005). "Neuropharmacokinetics of a new alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat". Drug Metabolism and Disposition. 33 (8): 1137–43. doi:10.1124/dmd.105.004424. PMID   15860654. S2CID   14891912.
  6. Béracochéa D, Philippin JN, Meunier S, Morain P, Bernard K (July 2007). "Improvement of episodic contextual memory by S 18986 in middle-aged mice: comparison with donepezil". Psychopharmacology. 193 (1): 63–73. doi:10.1007/s00213-007-0765-4. PMID   17384936. S2CID   39655878.
  7. Marighetto A, Valerio S, Jaffard R, Mormede C, Muñoz C, Bernard K, Morain P (May 2008). "The AMPA modulator S 18986 improves declarative and working memory performances in aged mice". Behavioural Pharmacology. 19 (3): 235–44. doi:10.1097/FBP.0b013e3282feb0c1. PMID   18469541. S2CID   20415746.
  8. Kelly SJ, Bernard K, Muñoz C, Lawrence RC, Thacker J, Grillo CA, Piroli GG, Reagan LP (January 2009). "Effects of the AMPA receptor modulator S 18986 on measures of cognition and oxidative stress in aged rats". Psychopharmacology. 202 (1–3): 225–35. doi:10.1007/s00213-008-1301-x. PMID   18762915. S2CID   35139538.
  9. Gupta SK, Mishra R, Kusum S, Spedding M, Meiri KF, Gressens P, Mani S (April 2009). "GAP-43 is essential for the neurotrophic effects of BDNF and positive AMPA receptor modulator S18986". Cell Death and Differentiation. 16 (4): 624–37. doi: 10.1038/cdd.2008.188 . PMID   19136940.
  10. Destot-Wong KD, Liang K, Gupta SK, Favrais G, Schwendimann L, Pansiot J, Baud O, Spedding M, Lelièvre V, Mani S, Gressens P (September 2009). "The AMPA receptor positive allosteric modulator, S18986, is neuroprotective against neonatal excitotoxic and inflammatory brain damage through BDNF synthesis". Neuropharmacology. 57 (3): 277–86. doi:10.1016/j.neuropharm.2009.05.010. PMID   19501111. S2CID   1400467.